Metagenomi Therapeutics
(NASDAQ) MGX
Metagenomi Therapeutics Financials at a Glance
Market Cap
$46.68M
Revenue (TTM)
$22.33M
Net Income (TTM)
-$85.89M
EPS (TTM)
-$2.29
P/E Ratio
-0.54
Dividend
$0.00
Beta (Volatility)
1.15 (Average)
Dividend
$0.00
Beta (Volatility)
1.15 (Average)
Price
$1.21
Volume
43,453.044
Open
$1.24
Price
$1.21
Volume
43,453.044
Open
$1.24
Previous Close
$1.24
Daily Range
$1.20 - $1.29
52-Week Range
$1.13 - $3.95
Estimated Earnings Date
Aug 11, 2026
Dividend
$0.00
Beta (Volatility)
1.15 (Average)
Price
$1.21
Volume
43,453.044
Open
$1.24
Previous Close
$1.24
Daily Range
$1.20 - $1.29
52-Week Range
$1.13 - $3.95
Estimated Earnings Date
Aug 11, 2026
MGX News
Motley Fool Moneyball Superscore
Our CEO Is Handing Members His Secret Weapon
It's called Motley Fool Moneyball, our new proprietary AI tool
We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.
Get Access NowAbout Metagenomi Therapeutics
Industry
Biotechnology
Sector
Health CareEmployees
119
CEO
Jian Irish, PhD, MBA
Website
www.metagenomi.coHeadquarters
Emeryville, 94608, US
MGX Financials
Key Financial Metrics (TTM)
Gross Margin
-12.54%
Operating Margin
-415.48%
Net Income Margin
-384.61%
Return on Equity
-51.23%
Return on Capital
-48.19%
Return on Assets
-43.61%
Earnings Yield
-1.85%
Dividend Yield
0.00%
Payout Ratio
0.00%
Stock Overview
Market Cap
$46.68M
Shares Outstanding
37.65M
Volume
43.45K
Avg. Volume
179.68K
Financials (TTM)
Gross Profit
-$2.80M
Operating Income
-$92.78M
EBITDA
-$80.80M
Operating Cash Flow
-$87.23M
Capital Expenditure
-$311.00K
Free Cash Flow
-$87.54M
Cash & ST Invst.
$140.16M
Total Debt
$39.19M
Metagenomi Therapeutics Performance Analysis
Revenue Growth Rate
Annual and quarterly growth comparisonEarnings Per Share Growth Rate
Annual and quarterly EPS growth comparisonQuarterly Performance
Revenue
$1.25M
-69.8%
Gross Profit
$1.25M
+105.9%
Gross Margin
100.00%
N/A
Market Cap
$46.68M
N/A
Market Cap/Employee
$231.10K
N/A
Employees
202
N/A
Net Income
-$23.06M
+7.9%
EBITDA
-$21.77M
+7.7%
Quarterly Fundamentals
Total Cash
$140.16M
-38.0%
Total Debt
$39.19M
-11.8%
Accounts Receivable
$1.00M
-1.2%
Inventory
$0.00
N/A
Long Term Debt
$33.08M
-14.8%
Short Term Debt
$6.11M
+9.0%
Return on Assets
-43.61%
N/A
Return on Invested Capital
-53.18%
N/A
Free Cash Flow
-$21.20M
+8.3%
Operating Cash Flow
-$21.18M
+7.3%